

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 61832

Title: Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside

Reviewer's code: 00505755

Position: Editorial Board

Academic degree: PhD

Professional title: Senior Research Fellow

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2020-12-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-12-22 04:05

Reviewer performed review: 2020-12-25 06:24

Review time: 3 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is an interesting and comprehensive review on early diagnosis of hepatocellular carcinoma (HCC). The detailed information of miR-125b, miR-122 and miR-21 as biomarkers for the early detection of HCC may be added in non-coding RNA section.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 61832

Title: Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside

Reviewer's code: 00071178

Position: Editor-in-Chief

Academic degree: FACS, FICS, MD, PhD

Professional title: Professor, Surgeon

Reviewer's Country/Territory: Turkey

Author's Country/Territory: China

Manuscript submission date: 2020-12-21

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2020-12-22 06:31

Reviewer performed review: 2021-01-03 12:26

Review time: 12 Days and 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

SPECIFIC COMMENTS TO AUTHORS

HCC is among the most common and mortality cancers in many countries of the world. HCC mostly develops secondary to some underlying diseases. Today, the best screening method for HCC is US + AFP measurements. however, it is known that some HCCs do not produce AFP. So it is obvious that there is a need for a new biomarker in screening. However, epidemiologically, a biomarker must be cheap and easily accessible in order to be used in screening. Markers used in current studies are quite expensive. Considering that the countries where HCC is most common are the underdeveloped countries, it is obvious that this issue should be discussed. I think the article is publishable